Regeneron 4th-quarter profit beats on rising Eylea sales

Thu Feb 14, 2013 6:53am EST

Feb 14 (Reuters) - Regeneron Pharmaceuticals Inc's quarterly profit beat market estimates for the sixth straight quarter as sales of its eye drug Eylea continued to zoom.

The company posted a fourth-quarter net profit of $470 million, or $4.08 per share, compared with a net loss of $53.4 million, or 58 cents per share, a year earlier.

The company's adjusted profit of $1.22 per share, according to Thomson Reuters I/B/E/S, beat analysts' estimates of $1.10 per share.

Total revenue for the quarter more than tripled to $414.6 million.

Eylea, which is co-marketed by Germany's Bayer AG , raked in U.S. sales of $276 million.

Analysts expected revenue of $392.6 million.

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article